MYSTERIOUS: 2 - What They Never Told You

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Al Jazeera · Jul 6, 2023

Eisai Alzheimer's drug gets full US approval, widening access to the therapy

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Tribune News Service · Jul 6, 2023

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Axios · Jul 6, 2023

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Axios · Jun 9, 2023

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year

The Independent UK · Jun 9, 2023

UK on verge of new dawn for dementia treatments, says taskforce chair

Today’s generation of older people could be last to face untreatable Alzheimer’s – but only if NHS overhauls care

The Guardian - UK · Apr 26, 2023

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service · Mar 13, 2023

Why a new Alzheimer's drug is having a slow US debut

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away

The Independent UK · Feb 4, 2023

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

StockNews.com · Feb 1, 2023

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune · Jan 30, 2023